These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36734081)

  • 1. HBsAg (-)/HBsAb (-)/HBeAg (-)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy.
    Shui LP; Zhu Y; Duan XQ; Chen YT; Yang L; Tang XQ; Zhang HB; Xiao Q; Wang L; Liu L; Luo XH
    J Med Virol; 2023 Feb; 95(2):e28549. PubMed ID: 36734081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation.
    Chen YM; Chen HH; Huang WN; Chen YH; Hsieh TY; Yang SS; Lan JL; Chen DY
    Int J Rheum Dis; 2019 Jun; 22(6):1145-1151. PubMed ID: 31117160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining Whether Prophylactic Antiviral Treatment Is Necessary in HBsAg-Negative/HBcAb-Positive Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Zhang A; Wu Y; Tan Y; Shi J; Zhao Y; Hu Y; Yu J; Zheng W; Lai X; Zhang M; Zhu Y; Ye Y; Huang Y; Fu S; Huang H; Luo Y
    Biol Blood Marrow Transplant; 2020 May; 26(5):956-964. PubMed ID: 31962163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.
    Tang Z; Li X; Wu S; Liu Y; Qiao Y; Xu D; Li J
    Hepatol Int; 2017 Sep; 11(5):429-433. PubMed ID: 28856548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
    Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
    Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.
    Masarone M; De Renzo A; La Mura V; Sasso FC; Romano M; Signoriello G; Rosato V; Perna F; Pane F; Persico M
    BMC Gastroenterol; 2014 Feb; 14():31. PubMed ID: 24533834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
    Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
    Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
    Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.
    Mozessohn L; Chan KK; Feld JJ; Hicks LK
    J Viral Hepat; 2015 Oct; 22(10):842-9. PubMed ID: 25765930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg
    Kuo MH; Tseng CW; Lee CH; Tung CH; Tseng KC; Lai NS
    Sci Rep; 2020 Feb; 10(1):2456. PubMed ID: 32051458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of some hepatitis B virus markers among pregnant women attending antenatal clinic in Specialist Hospital Sokoto Nigeria.
    Erhabor O; Mohammad SY; Bello L; Onuigwe FU; Abdulrahman Y; Zama I; Buhari H; Bagudo A; Ibrahim K; Ahmed M; Udomah FP; Adias TC; Erhabor T; Okara GC
    Hum Antibodies; 2020; 28(3):233-243. PubMed ID: 32333583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis.
    Hong X; Xiao Y; Xu L; Liu L; Mo H; Mo H
    Immun Inflamm Dis; 2023 Feb; 11(2):e780. PubMed ID: 36840482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis.
    Fang J; Li W; Peng X; Tan Z; Tan M; Zhang C; Wang W; Xu Z; Zhou G
    Int Urol Nephrol; 2017 Mar; 49(3):475-482. PubMed ID: 28032257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study.
    Tsai YF; Yang CI; Du JS; Lin MH; Tang SH; Wang HC; Cho SF; Liu YC; Su YC; Dai CY; Hsiao HH
    PeerJ; 2019; 7():e7481. PubMed ID: 31565551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of hepatitis B infection in Tari District, Southern Highlands Province, Papua New Guinea.
    Sanders RC; Lewis D; Dyke T; Alpers MP
    P N G Med J; 1992 Sep; 35(3):197-201. PubMed ID: 1296422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
    Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; Gérolami R
    J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.
    Tien YC; Yen HH; Chiu YM
    Clin Exp Rheumatol; 2017; 35(5):831-836. PubMed ID: 28375829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney Transplantation From Hepatitis B Surface Antigen (HBsAg)-Positive Living Donors to HBsAg-Negative Recipients: Clinical Outcomes at a High-Volume Center in China.
    Wang XD; Liu JP; Song TR; Huang ZL; Fan Y; Shi YY; Chen LY; Lv YH; Xu ZL; Li XH; Wang L; Lin T
    Clin Infect Dis; 2021 Mar; 72(6):1016-1023. PubMed ID: 32100025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy.
    Visentini M; Pica A; D'Ippolito G; Sculco E; La Gualana F; Gragnani L; Miglionico M; Mazzaro C; Fiorilli M; Basili S; Martelli M; Di Rocco A; Casato M; Gentile G; Pulsoni A
    Ann Hematol; 2023 Dec; 102(12):3457-3463. PubMed ID: 37650886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.